PL377202A1 - Agregat o zwiększonej odkształcalności, zawierający co najmniej trzy środki amfipatyczne, dla usprawnienia transportu przez półprzepuszczalne bariery oraz do nieinwazyjnego podawania leku in vivo, zwłaszcza przez skórę - Google Patents

Agregat o zwiększonej odkształcalności, zawierający co najmniej trzy środki amfipatyczne, dla usprawnienia transportu przez półprzepuszczalne bariery oraz do nieinwazyjnego podawania leku in vivo, zwłaszcza przez skórę

Info

Publication number
PL377202A1
PL377202A1 PL377202A PL37720203A PL377202A1 PL 377202 A1 PL377202 A1 PL 377202A1 PL 377202 A PL377202 A PL 377202A PL 37720203 A PL37720203 A PL 37720203A PL 377202 A1 PL377202 A1 PL 377202A1
Authority
PL
Poland
Prior art keywords
application
amphipats
aggregate
vivo
skin
Prior art date
Application number
PL377202A
Other languages
English (en)
Inventor
Gregor Cevc
Ulrich Vierl
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,618 external-priority patent/US20040105881A1/en
Application filed by Idea Ag filed Critical Idea Ag
Publication of PL377202A1 publication Critical patent/PL377202A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL377202A 2002-10-11 2003-10-09 Agregat o zwiększonej odkształcalności, zawierający co najmniej trzy środki amfipatyczne, dla usprawnienia transportu przez półprzepuszczalne bariery oraz do nieinwazyjnego podawania leku in vivo, zwłaszcza przez skórę PL377202A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery

Publications (1)

Publication Number Publication Date
PL377202A1 true PL377202A1 (pl) 2006-01-23

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377202A PL377202A1 (pl) 2002-10-11 2003-10-09 Agregat o zwiększonej odkształcalności, zawierający co najmniej trzy środki amfipatyczne, dla usprawnienia transportu przez półprzepuszczalne bariery oraz do nieinwazyjnego podawania leku in vivo, zwłaszcza przez skórę

Country Status (21)

Country Link
EP (5) EP1815847A3 (pl)
JP (3) JP2006505619A (pl)
KR (1) KR20050055723A (pl)
CN (1) CN1703199B (pl)
AT (1) ATE381316T1 (pl)
AU (1) AU2003273977B2 (pl)
BR (1) BR0315148A (pl)
CA (1) CA2498938A1 (pl)
DE (1) DE60318227T2 (pl)
DK (1) DK1551370T3 (pl)
EA (1) EA010407B1 (pl)
ES (1) ES2298566T3 (pl)
HR (1) HRPK20050421B3 (pl)
IS (1) IS7776A (pl)
MX (1) MXPA05003744A (pl)
NO (1) NO20052281L (pl)
NZ (1) NZ538571A (pl)
PL (1) PL377202A1 (pl)
PT (1) PT1551370E (pl)
SI (1) SI1551370T1 (pl)
WO (1) WO2004032900A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
EP2200651A2 (de) * 2007-09-13 2010-06-30 Basf Se Verwendung von hydrophobin-polypeptiden als penetrationsverstärker
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
DK2437726T3 (en) * 2009-06-03 2018-08-13 Sequessome Tech Holdings Limited FORMS FOR TREATING DEEP TISSUE Pain
CA2774891A1 (en) 2009-08-21 2011-02-24 Targeted Delivery Technologies Limited Vesicular formulations
US20140017301A1 (en) * 2011-03-21 2014-01-16 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
GB2503845A (en) * 2011-03-21 2014-01-08 Gregor Cevc Optimised preparations of highly adaptable aggregates
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CN104936682B (zh) * 2012-10-26 2017-12-15 牛津纳米孔技术公司 微滴界面
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
EP3027219A1 (en) * 2013-07-31 2016-06-08 Sequessome Technology Holdings Limited Vesicles
CN105764917B (zh) * 2013-09-26 2021-10-08 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
CN105658782B (zh) * 2013-10-25 2018-08-07 凸版印刷株式会社 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法
DK3316856T3 (da) 2015-06-30 2021-06-28 Sequessome Tech Holdings Limited Blandede formuleringer
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US12514929B2 (en) 2017-04-03 2026-01-06 The Regents Of The University Of California Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
CN1320880C (zh) * 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers

Also Published As

Publication number Publication date
MXPA05003744A (es) 2005-09-20
ES2298566T3 (es) 2008-05-16
EA010407B1 (ru) 2008-08-29
EP1551370A1 (en) 2005-07-13
HK1079113A1 (en) 2006-03-31
BR0315148A (pt) 2005-08-16
WO2004032900A8 (en) 2005-03-31
CN1703199A (zh) 2005-11-30
DE60318227D1 (de) 2008-01-31
JP2006505619A (ja) 2006-02-16
IS7776A (is) 2005-03-30
EP1815846A2 (en) 2007-08-08
NO20052281L (no) 2005-07-07
EP1829527A3 (en) 2008-11-05
EP1815847A3 (en) 2008-11-05
HRP20050421A2 (en) 2005-12-31
EP1551370B1 (en) 2007-12-19
NZ538571A (en) 2007-05-31
JP4555111B2 (ja) 2010-09-29
EP1815846A3 (en) 2008-10-22
ATE381316T1 (de) 2008-01-15
WO2004032900A1 (en) 2004-04-22
KR20050055723A (ko) 2005-06-13
EP1829528A3 (en) 2008-11-05
EP1815847A2 (en) 2007-08-08
SI1551370T1 (sl) 2008-06-30
JP2009108070A (ja) 2009-05-21
PT1551370E (pt) 2008-02-07
EP1829527A2 (en) 2007-09-05
HRPK20050421B3 (en) 2007-06-30
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
NO20052281D0 (no) 2005-05-10
CN1703199B (zh) 2010-04-28
AU2003273977B2 (en) 2007-07-12
CA2498938A1 (en) 2004-04-22
EA200500632A1 (ru) 2005-12-29
JP2005213261A (ja) 2005-08-11
DE60318227T2 (de) 2008-12-04
AU2003273977A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
PL377202A1 (pl) Agregat o zwiększonej odkształcalności, zawierający co najmniej trzy środki amfipatyczne, dla usprawnienia transportu przez półprzepuszczalne bariery oraz do nieinwazyjnego podawania leku in vivo, zwłaszcza przez skórę
Johnson et al. Diagnosis and treatment of acute urinary tract infections
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
Li et al. Transport, metabolism and elimination mechanisms of anti-HIV agents
DE3786005D1 (de) Traeger zur freisetzung mit einem an eine amphiphile substanz gekoppelten wirkstoff.
UA83350C2 (ru) Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу
CA2330207A1 (en) Microneedle devices and methods of manufacture and use thereof
PT977555E (pt) Preparacoes farmaceuticas e metodos para a sua administracao localmente
JP2004536045A5 (pl)
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
FR2797875B1 (fr) Agglomerats spheriques de telithromycine, leur procede de preparation et leur application dans la preparation de formes pharmaceutiques
WO2004004705A3 (en) Pharmaceutical formulations for preparing drink products
ES2135476T3 (es) Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.
WO2002000170A3 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
Yagame et al. Clinical effect of dipyridamole in patients with IgA nephropathy
RU97105491A (ru) Способ приживления кожных тканей при пластических операциях
Kryzyna et al. State management issues on health care in dissertations defended in 2005
Boulton Combination drug treatment benefits patients with HIV.
Wheeler RG-1068 RepliGen
Shved et al. Emoxipine correction of lipid peroxidation disorders in patients with osteoarthrosis deformans
SE9902317D0 (sv) Bår
Cadman On the road with protease inhibitors
RU2002127274A (ru) Применение препарата ветом-7048 впервые в качестве лекарственного препарата при лечении атрофии мозга, гидроцефалии мозга
HUP0402242A3 (en) Use of 4-oxobutanoic acid derivatives in the treatment of inflammation

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)